MARKET

JBIO

JBIO

Jade Biosciences Inc
NASDAQ
23.36
-0.78
-3.21%
After Hours: 22.90 -0.46 -1.95% 16:45 05/15 EDT
OPEN
23.38
PREV CLOSE
24.13
HIGH
24.81
LOW
22.14
VOLUME
555.32K
TURNOVER
--
52 WEEK HIGH
28.00
52 WEEK LOW
6.57
MARKET CAP
1.15B
P/E (TTM)
-9.6728
1D
5D
1M
3M
1Y
5Y
1D
Jade Biosciences Files Prospectus Related To Resale Of Up To 39,542,339 Shares By Selling Stockholders
Benzinga · 19h ago
JADE BIOSCIENCES INC - PROSPECTUS FILED FOR RESALE OF UP TO 39,542,339 SHARES BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 20h ago
Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data
TipRanks · 4d ago
Jade Biosciences Is Maintained at Buy by Guggenheim
Dow Jones · 4d ago
Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $32
Benzinga · 4d ago
Jade Biosciences Price Target Raised to $34.00/Share From $24.00 by Wedbush
Dow Jones · 5d ago
Jade Biosciences Is Maintained at Outperform by Wedbush
Dow Jones · 5d ago
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $34
Benzinga · 5d ago
More
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Webull offers Jade Biosciences Inc stock information, including NASDAQ: JBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JBIO stock methods without spending real money on the virtual paper trading platform.